OCGN Oct 2024 2.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 0.7000 |
| Open | 0.5300 |
| Bid | 0.6000 |
| Ask | 0.9500 |
| Strike | 2.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.5300 - 0.5300 |
| Contract range | N/A |
| Volume | |
| Open interest | 90 |
GlobeNewswireOcugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
- GuruFocus.com
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.
© 2024 Yahoo. All rights reserved.